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Abstract
Background: Secreted protein, acidic and rich in cysteine (SPARC) is a matricellular protein that mediates cell-
matrix interactions. It has been shown, depending on the type of cancer, to possess either pro- or anti-tumorigenic
properties. The transcriptional regulation of the SPARC gene expression has not been fully elucidated and the
effects of anti-cancer drugs on this process have not been explored.
Results: In the present study, we demonstrated that chromatin remodeling factor Brg-1 is recruited to the
proximal SPARC promoter region (-130/-56) through an interaction with transcription factor Sp1. We identified Brg-
1 as a critical regulator for the constitutive expression levels of SPARC mRNA and protein in mammary carcinoma
cell lines and for SPARC secretion into culture media. Furthermore, we found that Brg-1 cooperates with Sp1 to
enhance SPARC promoter activity. Interestingly, fenretinide [N-4(hydroxyphenyl) retinamide, 4-HPR], a synthetic
retinoid with anti-cancer properties, was found to up-regulate the transcription, expression and secretion of SPARC
via induction of the Brg-1 in a dose-dependent manner. Finally, our results demonstrated that fenretinide-induced
expression of SPARC contributes significantly to a decreased invasion of mammary carcinoma cells.
Conclusions: Overall, our results reveal a novel cooperative role of Brg-1 and Sp1 in mediating the constitutive
and fenretinide-induced expression of SPARC, and provide new insights for the understanding of the anti-cancer
effects of fenretinide.
Background
Secreted protein acidic and rich in cysteine (SPARC),
also known as osteonectin and BM-40, is a matricellular
protein that mediates cell-matrix interaction [1,2].
SPARC plays a role in various physiological processes,
including cell adhesion, proliferation, migration, mor-
phogenesis and angiogenesis. It is also involved in pro-
cesses which require extracellular matrix turnover, such
as wound healing and tumor progression [3]. In recent
years, the role of SPARC as a modulator in the patho-
genesis of different malignancies has become increas-
ingly evident and its role in tumorigenesis appears to be
complex, dependent on cell type and tumor microenvir-
onment [4]. SPARC has been shown to function as a
tumor suppressor in neuroblastomas, as well as in ovar-
ian, lung, breast, pancreatic and nasopharyngeal cancers
[5-15]. Moreover, in tumor xenograft models, the
growth of pancreatic and lung cancers in SPARC
-/-
knockout mice was shown to be significantly enhanced
compared with wild-type mice [16,17]. One mechanism
proposed for the anti-tumorigenic properties of SPARC
is due to its ability to enhance apoptosis [18]. Addition-
ally, the up-regulated expression of SPARC was shown
to improve effectiveness of radiotherapy [19] and che-
motherapy [20,21] in colorectal cancers. Interestingly,
SPARC also has a pro-tumorigenic function linking its
expression with poor prognosis in certain human can-
cers such as melanoma, meningioma and prostate
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any medium, provided the original work is properly cited.cancer [22-25]. Therefore, more studies are warranted to
better delineate the regulation of SPARC and its role in
tumor progression.
The modulation of chromatin structure is an essential
component in the regulation of both transcriptional acti-
vation and repression. Brg-1, one of the ATPase subu-
nits of the SWI/SNF chromatin remodeling complex,
plays critical functions in SWI/SNF-mediated transcrip-
tional regulation [26]. It is well established that Brg-1 or
Brg-1-containing SWI/SNF complex is involved in either
transcriptional activation or transcriptional repression of
a subset of genes. For example, Brg-1 is required for the
activation of genes such as CD44 [27], MMP-2 [28] and
MMP-9 [29], and is required for the repression of genes
such as c-fos [30] and cyclin D1 [31]. In addition, Brg-1
has been shown to interact with tumor suppressor p53
[32,33] and b-catenin [34], leading to the transcriptional
activation of target genes, as well as tumor suppressor
prohibitin [35,36], TopBP [37] and HIC1 [38] mediating
transcriptional repression of target genes. As Brg-1 pro-
tein does not contain a sequence-specific DNA binding
domain, recruitment of Brg-1 or Brg-1-containing SWI/
SNF complex to target promoters requires protein-pro-
tein interaction between Brg-1 and other transcription
factors or transcription regulators. Previous studies have
shown that Brg-1 can be recruited to certain gene pro-
moters via its interaction with transcription factor Sp1
[39,40]. Meanwhile, another study demonstrated that
Sp1 is bound to the SPARC gene promoter and required
for activation of the latter [41]. Taken together, it is not
unreasonable to believe that Brg-1 may play an impor-
tant role in transcriptional regulation of SPARC gene
expression.
Fenretinide, a synthetic retinoid with anti-cancer prop-
erties, has been widely studied in chemoprevention clini-
cal trials. Prolonged treatment with this drug does not
lead to any induction of point mutations or chromoso-
mal aberrations and shows a favorable toxicity profile
compared with other classical retinoic acids [42,43]. In
rat models of breast cancer, fenretinide selectively accu-
mulates in breast tissue; it is thus particularly active in
inhibiting rat mammary carcinogenesis [43,44]. More-
over, in clinical trials, fenretinide decreases the occur-
rence of secondary breast cancers with a 50% risk
reduction in women aged 40 years or younger treated
with a low maintenance dose of fenretinide [45].
Furthermore, fenretinide inhibits cell growth through
the induction of apoptosis rather than differentiation
[46,47], an effect that is strikingly different from that of
the parental compound all-trans retinoic acid; it shows
synergistic response with chemotherapeutic drugs such
as cisplatin, carboplatin, etoposide or TRAIL/Apo2L
[48-50]. All of these properties make fenretinide an
attractive candidate for cancer chemoprevention and
chemotherapy [47,51]. However, the molecular mechan-
ism responsible for these divergent functions of the fen-
retinide has not yet been fully defined and deserves
further investigation.
In this study, we identified Brg-1 as a critical regulator
for the constitutive expression of the SPARC gene in
mammary carcinoma cell lines. We described, for the
first time, the functional importance of the interaction
between Brg-1 and Sp1 when binding to the SPARC
promoter. We also reported that fenretinide up-regu-
lates the SPARC gene expression via induction of Brg-1.
Finally, our results demonstrated that modulation of
SPARC is linked to metastatic cancer cell invasion.
Overall, our results reveal a novel regulatory mechanism
mediating the expression of SPARC and provide new
insights for the understanding of the anti-cancer effects
of fenretinide.
Results
Sp1 and Brg-1 bind to the SPARC promoter in mammary
carcinoma cell lines
The 5′-flanking region of the mouse SPARC gene has a
single major transcriptional start site; no TATA or
CAAT boxes but six repeats of a GGAGG sequence
within the proximal region of the SPARC promoter
(-124/+19) (Figure 1A), as described previously [52].
These characteristics are well conserved in the SPARC
gene among various species, including mouse, chicken,
cow and human [53]. This GGAGG sequence represents
o n et y p eo ft h er e g u l a t o r ys e q u e n c eG Cb o x( G C - I ) ,
which has been shown to bind transcription factor Sp1/
3, regulating transcriptional activity of several genes
including Adam8, Pgr and Adamts1 [54-56].
To determine whether Sp1 and Brg-1 bind to the
GGAGG repeats sequence present in the mouse SPARC
promoter, we employed an immobilized-template assay
using a biotin-tagged probe a (spanning from nucleotide
-130 to -56 of the SPARC promoter, Figure 1A), which
allowed us to isolate the transcription factors that bind
to this probe. Using Western blot analysis, we were able
to document that both Sp1 and Brg-1 interacted with
this region of the SPARC gene (Figure 1B, middle
panel). The negative control, p38, was not associated
with the probe a. A probe b (spanning from nucleotide
-50 to +19 of the SPARC promoter), used as a non-spe-
cific binding control, was bound neither by Sp1 nor by
Brg-1 (Figure 1B, right panel). The three well character-
ized mammary tumor cell lines (4T1, 168FARN and
67NR) used in our study are derived from a single,
spontaneously arising mouse mammary tumor which
differ from each other in their metastatic potential [57].
When injected into the mammary gland of mice, these
tumor lines are either non-metastatic (67NR), sponta-
neously metastatic to lymph node (168FARN) or
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Page 2 of 18Figure 1 Sp1 and Brg-1 are bound to the SPARC promoter in tumor cell lines. (A) Nucleotide sequence (from - 201 to +19) indicating the
position of six GGAGG boxes (underlined) in the mouse SPARC promoter. (B) Nuclear extracts were prepared from 4T1, 168FARN and 67NR cells.
Proteins which bind to probe a (spanning GGAGG-rich nucleotides -130/-56) or probe b (spanning nucleotides -50/+19) were isolated from the
nuclear extracts using the immobilized-template assay and then subjected to Western blot analysis with antibodies against Brg-1, Sp1 or p38.
p38 and the probe b were used to serve as a non-specific binding control (right panel). Unpurified total nuclear extracts were also subjected to
Western blot analysis and probed with the same antibodies (left panel). (C) Cross-linked and sonicated chromatin samples were prepared from
4T1, 168FARN and 67NR cells. ChIP assays were performed using antibodies against Sp1, Brg-1 or non-specific rabbit IgG as a control.
Immunoprecipitated DNA and serially diluted input genomic DNA was amplified with primers specific to the SPARC promoter. PCR products
were then analyzed using 2.0% agarose gels and stained with ethidium bromide. The illustrated results are representative of three independent
experiments. (D) The ChIP DNA and input genomic DNA from (C) were quantified and amplified by real-time qPCR as described in the Materials
and Methods section. The occupancy level of Brg-1 or Sp1 at the SPARC promoter is represented as the ratio of signal from IP samples versus
that of the input minus background of IgG control. The relative occupancy level of Brg-1 or Sp1 in 4T1 cells is set as 1. Data represented as
mean ± SEM (n = 3).
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Page 3 of 18metastatic to lung, liver, bone and brain via the hemato-
genous route (4T1) [58]. The nuclear expression of Sp1
and Brg-1 were also determined by Western blot analy-
sis. As shown in Figure 1B (left panel), there was no
obvious difference in the protein level of Sp1 present in
the three cell lines; whereas the protein level of Brg-1
declined in a concordant manner with the increase of
metastatic potential, the latter being highest in non-
metastatic 67NR cells, intermediate in partly metastatic
168FARN cells and lowest in highly metastatic 4T1
cells. To investigate whether Sp1 and Brg-1 are asso-
ciated with the proximal region of the SPARC gene in
living cells, we performed ChIP assays using antibodies
to Sp1 and Brg-1, and nonspecific IgG as a control. A
pair of primers spanning a 179-bp DNA fragment
(-201/-23) of the proximal region encompassing the
GGAGG repeats was used for PCR. As shown in Figure
1C, both the antibodies recognizing Sp1 and Brg-1 pre-
cipitated this promoter fragment, while the nonspecific
IgG failed to do so. Further, the occupancy levels of
B r g - 1a n dS p 1a tt h eS P A R Cp r o m o t e rw e r ea n a l y z e d
by quantitative ChIP analysis. We found that, consistent
with the nuclear Brg-1 protein level, Brg-1 occupancy
likewise decreased in a concordant manner with the
increase of metastatic potential in the three cell lines.
The difference of Sp1 occupancy level was not signifi-
cantly different among the three cell lines (Figure 1D).
Our results demonstrate that both Sp1 and Brg-1 bind
to the same proximal region of the SPARC promoter
and that the level of Brg-1 expression and its binding to
the SPARC promoter seem to negatively correlate with
the metastatic potential of the three cell lines.
Sp1 is essential for the recruitment of Brg-1 to the SPARC
promoter
To determine whether Sp1 is specifically responsible for
recruitment of Brg-1 to the SPARC promoter, we
knocked down Sp1 expression using RNA interference.
The effect of Sp1 knockdown on the binding of Brg-1 to
the GGAGG repeats sequence of the SPARC promoter
was then analyzed by using an immobilized-template
assay. As shown in Figure 2A, transfection of specific
Sp1 siRNAs into 4T1 cells led to a substantial down-
regulation of Sp1 protein levels (decreased by > 76%),
without any effect on Brg-1 protein expression. Trans-
fection using a control siRNA had no effect on either
Sp1 or Brg-1 levels. Interestingly, binding of Brg-1 to
the SPARC promoter was significantly diminished when
using nuclear extract from Sp1 siRNA-transfected cells
(Figure 2B). To further test the role of Sp1 in mediating
Brg-1 binding to the SPARC promoter in living cells, a
ChIP-qPCR assay was performed using 4T1 cells trans-
fected with Sp1 siRNA. As shown in Figure 2C, trans-
fection with Sp1 siRNA significantly diminished the
amount of Brg-1 bound to the SPARC promoter. These
results suggest that the Sp1 transcription factor is essen-
tial for efficient binding of Brg-1 to the SPARC
promoter.
Interaction of Sp1 and Brg-1 in intact cells
Since depletion of Sp1 diminished Brg1 binding to the
SPARC promoter, we postulated that Brg-1 is recruited
to the SPARC promoter by forming a complex with
Sp1. To test this hypothesis, we performed co-immuno-
precipitation experiments using nuclear extracts from
4T1, 168FARN and 67NR cells. As shown in Figure 3A,
Sp1 was found in the complex with Brg-1, but not with
the IgG control. These co-immunoprecipitation assays
were repeated in a reciprocal fashion using an anti-Sp1
antibody. Association of Sp1 and Brg-1 was again
detected by immunoblotting of these complexes with
anti-Brg-1 antibodies (Figure 3B). We next determined
by re-ChIP analyses whether Brg-1 is associated with
the Sp1-containing SPARC promoter fragment in living
cells. Briefly, chromatin fragments from cross-linked
4T1, 168FARN and 67NR cells were first immunopreci-
pitated using antibodies against Sp1. The resulting
immunocomplex was then eluted and subjected to
immunoprecipitation using antibodies against Brg-1.
PCR analysis was then used to determine whether the
promoter fragment was present in the final precipitate.
As shown in Figure 3C, we found that the promoter
fragment present in the first immunocomplex generated
using anti-Sp1 antibodies was pulled down again by
anti- Brg-1 antibodies. These results indicate an associa-
tion between Brg-1 and Sp-1 at the proximal promoter
region containing GGAGG repeats in these cells.
Brg-1 is required for expression of the SPARC gene
To further confirm the importance of Brg-1 in SPARC
gene expression, we used RNA interference to deplete
endogenous Brg-1. As shown in Figure 4A, transfection
of 4T1 cells with different concentrations of siRNA tar-
geting Brg-1 (0-50nM) resulted in an inhibition of Brg-1
mRNA expression in a dose-dependent manner (upper
panel), accompanied by a dose-dependent decrease in
SPARC mRNA level (bottom panel). Furthermore, Wes-
tern blot analysis showed that transfection with 30 nM
of Brg-1 siRNA led to a substantial down-regulation of
Brg-1 protein levels (>80% decrease), with no effect on
transcription factor Sp1 and b-actin expression. Trans-
fection using a control siRNA had no effect on Brg-1,
Sp1 or b-actin protein levels. Similarly to what was
observed in the Sp1 knockdown experiments also,
SPARC protein level was significantly inhibited in Brg-1
knockdown cells (reduced by 69%, Figure 4B). As
SPARC is a secreted protein, in order to investigate if
Brg-1 knockdown also leads to a decrease of SPARC
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collected for Western blot analysis. As shown in Figure
4C, a marked decrease in secreted SPARC was detected
in the media harvested from Brg-1 siRNA-transfected
cells in comparison to mock-treated cells. The cell-free
medium (Med) was used as a control and no signal was
detectable using the specific antibody against murine
SPARC. To correct for any potential discrepancy in cell
number resulting from different experimental condi-
tions, densitometric quantitation was performed and
results were adjusted for total protein amounts of cell
lysates. After correction, SPARC secretion reduced by
72% in Brg-1 knockdown cells compared with mock-
treated cells (P < 0.001). To further study the influence
of Brg-1 on SPARC promoter activity, we generated a
reporter pREP4-SP-Luc which contains a 220 bp
Figure 2 Sp1 mediates the recruitment of Brg-1 to the proximal region of the SPARC gene. 4T1 cells were transfected with mock
(transfection reagent only), siRNA control (CTR), or siRNA specific for Sp1, and then cultured for 72 hrs prior to harvesting the cells. (A) Total cell
extracts were prepared from transfected cells, and protein expression was analyzed by Western blotting using antibodies specific to Sp1, Brg-1 or
p38. (B) Nuclear extracts were prepared and the binding reactions of Sp1, Brg-1 or p38 to the probe a were analyzed using the immobilized-
template assay followed by Western blot analysis. (C) Cells were cross-linked and sonicated, and ChIP assay was performed. The precipitated
DNAs and input DNA were quantified and then amplified using real-time qPCR. The occupancy level of Brg-1 at the SPARC promoter is
calculated as described in Figure 1 D. The relative occupancy level of Brg-1 in mock-treated cells is set as 100%. Data represented as mean ±
SEM (n = 3).
Figure 3 Brg-1 and Sp1 are components of the same nuclear complexes. (A) Nuclear extracts from 4T1, 168FARN and 67NR cells were
immunoprecipitated (IP) using Brg-1 antibodies or rabbit IgG (control). The immunoprecipitates were subjected to SDS/PAGE gel followed by
Western blot analysis using antibodies against Sp1 and Brg-1. (B) The co-immunoprecipitation assay was carried out by using Sp1 antibody or
rabbit IgG for the IP and Brg-1 or SP1 antibodies for the Western blot analysis. (C) 4T1, 168FARN and 67NR cells were cross-linked and subjected
to sonication and immunoprecipitation with the indicated antibodies. ChIP was first carried out using the Sp1 antibody, and the
immunocomplexes were eluted using 10 mM dithiothreitol. The aliquots of the diluted elution were immunoprecipitated with Brg-1, or non-
specific IgG as a control. The precipitated DNA fragments were amplified by PCR using the primers specific to the SPARC promoter region
containing GGAGG repeats (spanning nucleotides -201/-23). The illustrated results are representative of three independent experiments.
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Page 5 of 18Figure 4 Brg-1 is required for SPARC gene expression. RNA interference- mediated depletion of Brg-1 reduces SPARC expression. 4T1 cells
were transfected with mock, siRNA control or different concentrations of siRNA targeting Brg-1[0(mock)-50 nM] and were then cultured for
another 48 hrs prior to harvesting the cells. (A) Total RNA was isolated from transfected 4T1 cells and mRNA levels of Brg-1 and SPARC were
analyzed using real-time RT-qPCR. The relative mRNA level of Brg-1 or SPARC was represented as a percentage of the Brg-1 or SPARC mRNA
level in mock-treated 4T1 cells (data shown are mean ± SEM, n = 4). (B) Total cell extracts were prepared from siRNA-transfected (30 nM) or
mock-transfected 4T1 cells. Western blot analysis was performed to assess the protein expression levels of Brg-1, SPARC, Sp1 and b-actin (upper
panel). Quantification of the protein expression of Brg-1, SPARC and Sp1 (data shown are mean ± SEM, n = 3) (bottom panel). **P < 0.001,
compared with mock-treated cells. (C) Conditioned media were collected from siRNA-transfected (30 nM) or mock-transfected 4T1 cells, and the
levels of secreted SPARC were assessed by Western blot analysis. Cell-free medium (Med) was used as a control. Densitometric quantitation was
performed and results were adjusted for total protein content of cell lysate (densitometry/μg cell total protein). The relative level of secreted
SPARC in the medium of mock-transfected 4T1 cells is set as 100%. Data represented as mean ± SEM (n = 3). (D) Overexpression of Brg-1
enhances the SPARC promoter-driven reporter gene transcription. 4T1 cells were co-transfected with the luciferase reporter vector pREP4-SP-Luc
and expression plasmids encoding Brg-1 or its mutant (Brg-1
K798R) or empty plasmids (control). Cell lysates were prepared 48 hrs after
transfection and assayed for luciferase activity. Luciferase relative activity is expressed as a fold of the luciferase activity of the cells untransfected
with Brg-1. The data shown (mean ± SEM) are the averages of three independent experiments performed in triplicate.
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-201 to +19). This particular promoter region of the
SPARC gene was previously shown to be necessary and
sufficient to maintain constitutive SPARC gene expres-
sion, and our present results demonstrated that both
Sp1 and Brg-1 are bound to this promoter region. The
SPARC promoter-luciferase reporter was then intro-
duced into 4T1 cells with an empty plasmid (as a con-
trol) or a plasmid expressing wild-type Brg-1 or mutant
Brg-1 (K798R) defective in ATPase activity. Luciferase
activity was determined 48 hrs later. As shown in Figure
4D, overexpression of wild-type Brg-1 significantly aug-
mented the luciferase activity driven by the SPARC pro-
moter, whereas mutant Brg-1 (K798R) had a much less
pronounced enhancing effect on the luciferase activity.
These results document a causal relationship between
the level of Brg-1 protein and SPARC gene expression.
Brg-1 enhances SPARC promoter activity in a Sp1-
dependent manner
To test if the Sp1 is required for the Brg-1-mediated
transcriptional activation of the SPARC gene, we intro-
duced Sp1 siRNAs and Brg-1 expression plasmids into
the 4T1 cells to inhibit the expression of the Sp1 and
enhance the expression of the Brg-1. As shown in Figure
5A, overexpression of Brg-1 increased the SPARC pro-
moter-driven reporter gene expression by 4.7-fold in
4T1 cells without Sp1 knockdown, whereas knocking
down Sp1 reduced the induction of SPARC promoter-
driven reporter gene expression by Brg-1 from 4.7-fold
to 0.7-fold. These results demonstrate that Sp1 plays an
important role in Brg-1 mediated transcriptional activa-
tion of the SPARC gene.
To exclude the possibility that Sp1 siRNAs may mod-
ify Brg-1 protein expression, we examined Brg-1 protein
levels in 4T1 cells transfected with control siRNA or
siRNA specific for Sp1. As shown in Figure 5B, knock-
down of Sp1 did not make a significant impact on the
Brg-1 expression level (compare lanes 1 and 2 as well as
lanes 3 and 4). The effect of Brg-1 overexpression on
the Sp1 protein expression was also analyzed in 4T1
cells transfected with empty or Brg-1-encoding plasmids.
Similarly, Sp1 protein expression was not affected signif-
icantly by the overexpression of Brg-1 protein (compare
lanes 1 and 3).
Endogenous SPARC expression correlates with Brg-1
expression levels
We found that the endogenous expression of Brg-1
decreased in a concordant manner with the increase of
metastatic potential among the three tumor cell lines.
We next documented a causal relationship between the
level of Brg-1 protein and SPARC gene expression in
4T1 cells. These observations led us to believe that the
difference of Brg-1 gene expression could be responsible
for the differential expression of SPARC in the three cell
lines. To investigate, the SPARC mRNA and protein
levels were assessed. As we expected, in parallel with
the Brg-1 protein level, the SPARC mRNA and protein
levels were highest in 67NR, intermediate in 168 FARN
and lowest in 4T1 cells (Figures 6A, B and Figure 1B,
left panel). In addition, Western blot analysis of secreted
proteins demonstrated that the amount of released
SPARC in the conditioned medium is correlated with
the intracellular mRNA and protein expression levels of
this gene (compare Figure 6C with Figure 6A and 6B).
Figure 5 Inhibition of endogenous Sp1 protein decreased the Brg-1-mediated transcriptional activation of the SPARC gene. 4T1 cells
were respectively transfected with siRNA control (-) or siRNAs specific for Sp1 (+). 24 hrs after transfection, the luciferase reporter construct
pREP4-SP-luc was co-transfected with Brg-1 expression plasmid or empty plasmid (control) into 4T1 cells. Cell lysates were prepared 48 hrs after
the second transfection. (A) The luciferase activity was analyzed. The data shown (mean ± SEM) are the averages of three independent
experiments performed in triplicate. (B) Protein expression levels of Sp1, Brg-1 and b-actin (internal control) in transfected 4T1 cells were
assessed using Western blot analysis. The illustrated result is a representative of three independent experiments.
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secretion are correlated with the Brg-1 expression level.
Our results also suggest that higher expression and
secretion of SPARC might be correlated with lower
metastatic potential of mammary carcinoma cells.
Expression and secretion of the SPARC is up-regulated by
fenretinide treatment in mammary tumor cell lines
Fenretinide has been shown to have a long-term protec-
tive effect against secondary breast cancers [45,51,59].
Since we observed an interesting association between
the relatively low level of SPARC expression and the
high metastatic potential of 4T1 cells, we postulated
that treatment with fenretinide might reverse the
tumorigenic ability of these cells by affecting the expres-
sion of SPARC. To test this hypothesis, the expression
of SPARC was detected by RT-qPCR and Western blot
analysis in 4T1, 168 FARN and 67NR cells treated with
fenretinide at different concentrations (0-5 μM) for 24
hrs. As shown in Figures 7A and B, fenretinide induced
the expression of SPARC mRNA and protein in a dose-
dependent manner. To investigate if fenretinide affects
the secretion of SPARC protein, culture media were col-
lected from the 4T1 and 67NR cells treated with fenreti-
nide for 24 hrs and secreted SPARC was assessed. As
expected, fenretinide increased the secretion level of
SPARC into the extracellular media in a dose-dependent
manner, too (Figure 7C). To test whether the fenreti-
nide-induced expression of SPARC resulted from the
transcriptional activation, reporter vectors (pREP4-SP-
Luc) were transfected into the three cell lines. The
transfected cells were then left untreated or treated with
different concentrations of fenretinide for 24 hrs. As
shown in Figure 7D, fenretinide increased SPARC pro-
moter-driven luciferase activity in all three cell lines in a
dose-dependent manner. The results demonstrate that
fenretinide treatment increases the transcriptional activ-
ity and expression of the SPARC gene.
Effects of Sp1/Brg-1 on the fenretinide-induced
transactivation of SPARC gene
To explore in detail fenretinide-induced transcriptional
activation of the SPARC gene, the expression and the
ability of Brg-1 and Sp1 binding to the SPARC promoter
were analyzed in all three cell lines in response to
fenretinide treatment. As shown in Figures 8A and 8B,
fenretinide induced the expression of Brg-1 in a dose-
dependent manner, while it had no significant effect on
the expression of Sp1. In addition, treatment of cells
with fenretinide increased the interaction between Sp1
and Brg-1 (Figure 8C). To directly examine the effect of
fenretinide on the binding of Brg-1 and Sp1 proteins to
the SPARC promoter, we performed ChIP-qPCR to
assess the occupancy level of Brg-1 and Sp1. As shown
in Figure 8D, the occupancies of Brg-1 protein at the
selected promoter region increased upon fenretinide
treatment in a dose-dependent manner. Fenretinide had
slight/no effect on occupancy level of Sp1 at this region.
Figure 6 Analyses of SPARC expression and secretion from mammary tumor cell lines with different metastatic capacities. Cells were
seeded into 6-well plates at a density of 1 × 10
5 cells (4T1 or 168FARN) or 1.5 × 10
5 cells (67NR) per well and cultured at 37°C. Cell-free
medium served as a control. Seventy-two hrs after culture, cell media were collected, and total RNA as well as protein extracts were prepared
from the three cell lines. (A) Real-time qRT-PCR was used to analyze the relative expression of SPARC mRNA level. The SPARC mRNA was
normalized by GAPDH expression and the relative expression level is represented as a fold of the SPARC mRNA level in 4T1 cells. (Data
represented as mean ± SEM, n = 4). *P < 0.01, compared with 4T1; **P < 0.01, compared with 168FARN. (B) Cellular SPARC protein expression
was assessed using Western blot analysis. The illustrated result is a representative of three independent experiments. (C) The levels of secreted
SPARC protein in the culture media were assessed by Western blot analysis. Cell-free medium (Med) was used as a control. Densitometric
quantitation was performed and results were adjusted for total protein content of cell lysate (densitometry/μg cell total protein). The relative
level of secreted SPARC in the medium of 4T1 cells is set as 1. Data represented as mean ± SEM (n = 3). *P < 0.01, compared with 4T1;
**P < 0.01, compared with 168FARN.
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Page 8 of 18Figure 7 Fenretinide treatment increases SPARC expression and secretion from mammary carcinoma cells. 4T1, 168FARN or 67NR cells
were treated with various concentrations of fenretinide (1.25 μM, 2.5 μM and 5 μM) or left untreated (control) for 24 hrs. (A) Total RNA was
isolated from different cell lines and SPARC mRNA level was analyzed using real-time RT-qPCR. Experiments were conducted in quadruplicate
and normalized to GAPDH mRNA level. The relative SPARC mRNA level is represented as a fold of the SPARC mRNA level in untreated cells (data
shown are mean ± SEM, n = 4). Compared with control, *P < 0.05, **P < 0.01, ***P < 0.001. (B) Total protein extracts were prepared from
different cell lines and expression of SPARC protein levels were assessed using Western blot analysis. Expression of b-actin was used as an
internal control. (C) Conditioned media were collected from 4T1 (left panel) and 67NR (right panel) cell lines and the levels of secreted SPARC
protein were assessed by Western blot analysis. Densitometric quantitation was performed and results were adjusted for total protein content of
cell lysate (densitometry/μg cell total protein). The relative level of secreted SPARC in the medium of untreated cells is set as 1. Data represented
as mean ± SEM (n = 3). Compared with control, ***P < 0.001. (D) Effect of fenretinide treatment on the transcriptional activity of the SPARC
promoter. 4T1, 168FARN and 67NR cells were transiently co-transfected with the luciferase reporter vector pREP4-SP-Luc and pRL-CMV. The pRL-
CMV reporter was used as an internal control. 24 hrs after transfection of plasmids, cells were cultured for 24 hrs with or without different
concentrations of fenretinide, and the luciferase activity was analyzed by the dual-luciferase reporter assay system. Luciferase relative activity is
presented as a fold of the luciferase activity of the cells without fenretinide treatment. The data shown (mean ± SEM) represent the averages of
three independent experiments performed in triplicate.
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mation of the Sp1/Brg-1 complex, resulting in facilitat-
ing the access of Brg-1 to the SPARC promoter and
enhancing the transactivation of this gene.
Brg-1 mediates the fenretinide-induced transactivation of
SPARC
Since the expression of Brg-1 as well as the formation
and binding of Sp1/Brg-1 to the SPARC promoter were
increased in fenretinide-treated cells, it is likely that
Brg-1 is involved in fenretinide-induced transcriptional
activation of the SPARC gene. We employed Brg-1 siR-
NAs to knockdown Brg-1, and its effect on fenretinide-
induced transcriptional regulation of the SPARC gene
was then assessed by luciferase reporter assays. As
shown in Figure 9A, fenretinide-induced promoter activ-
ity was significantly inhibited in Brg-1 knockdown cells.
Interestingly, fenretinide-induced SPARC gene expres-
sion was significantly inhibited both at the protein and
mRNA levels in Brg-1 knockdown cells (Figures 9B and
9C, respectively). These results reveal that the Sp1/Brg-1
complex plays an important role in fenretinide-induced
SPARC gene expression, demonstrating that the Brg-1
protein is responsible for fenretinide-induced SPARC
gene transactivation.
SPARC is involved in fenretinide-induced cell invasion
inhibition
Fenretinide has been shown to inhibit the invasion of
several cancer cell types, including breast cancer [60],
ovarian cancer [61], prostate cancer [62] and Kaposi’s
sarcoma [63]. Therefore, we next tested whether fenreti-
nide as well as fenretinide-induced SPARC expression
have effects on the migration and invasion of 4T1 cells.
Our results demonstrated that fenretinide suppressed
the cell motility in a dose-dependent manner and the
inhibition of cell motility was not significantly affected
by addition of anti-SPARC antibodies (Figure 10A).
Similarly, 4T1 cells treated with fenretinide showed a
significant decrease in cell invasion compared with
untreated cells. However, when cells were incubated
with anti-SPARC antibodies, we found that cell invasion
inhibited by fenretinide treatment was partly restored.
On the contrary, addition of non-specific goat IgG had
Figure 8 Fenretinide induces the expression of Brg-1, Brg-1 and Sp1 complex formation and the binding of Brg-1 to SPARC promoter.
4T1, 168FARN or 67NR cells were left untreated (control) or treated with the indicated doses of fenretinide for 24 hrs. Cell lysates were prepared,
and assessed by Western blot analysis for Brg-1 (A) and Sp1 (B), respectively. Expression of b-actin was detected as an internal control. (C)
Nuclear extracts from fenretinide-treated 4T1 cells were immunoprecipitated (IP) with antibodies against Sp1 or IgG (control). The precipitated
protein complexes were subjected to SDS/PAGE and analyzed by Western blot analysis with an antibody against Brg-1 or Sp1. (D) Cross-linked
chromatin derived from either fenretinide-treated or untreated 4T1 cells was immunoprecipitated with Brg-1or Sp1 antibodies or nonspecific IgG.
The precipitated DNAs or input DNA were analyzed by real-time qPCR with the specific primers for the region from -201 to -23 nucleotides of
the SPARC promoter. The relative occupancy level of Brg-1 or Sp1 in untreated 4T1 cells (CTR) was set as 1. Data shown are mean ± SEM (n = 3)
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is one of the mediators involved in the fenretinide-
induced suppression of cell invasion.
Discussion
SPARC is a single-copy gene with a high degree of evo-
lutionary conservation. The mouse SPARC gene is 92%
identical to the human homologue. The 5′-proximal
flanking region of the SPARC gene displays a well-con-
served and characterized GGAGG repeats sequence
[52,53]. The activity of the human SPARC promoter
requires a purine-rich region with GGAGG repeats
(within the -120/-70 fragment) in human breast cancer
MCF7 cell line, and the transactivation of the SPARC
promoter is dependent on the transcription factor Sp1/3
in Drosophila SL2 cells [64]. Furthermore, it was shown
that Sp1/3 is required for constitutive activation of the
chicken SPARC promoter (-124/+16), by directly bind-
ing to the GGA-rich, -92/-57 fragment [41]. These
results suggest that constitutive transcription of SPARC
might be regulated by similar mechanisms in various
species. Indeed, our present study demonstrated that
Sp1 is bound to the GGAGG repeat region within the
mouse SPARC promoter, which is consistent with pre-
vious findings in chicken and human SPARC genes.
W h a ti sm o r e ,w ef o u n df o rt h ef i r s tt i m et h a tS p 1i s
essential for the recruitment of Brg-1 to the SPARC
promoter (within the -130/-56 fragment) via interaction
with each other. We demonstrated that inhibition of
Brg-1 significantly reduces the expression of the SPARC
gene, and Brg-1 cooperates with Sp1 to enhance the
SPARC promoter activity. These results suggest that Sp1
and Brg-1 work together to maintain a constitutive
expression level of the SPARC gene. We found that
there exist significant differences in the levels of endo-
genous SPARC mRNA and protein expression as well as
secreted SPARC among the three tumor cell lines, with
these levels being highest in the non-metastatic 67NR
cells, intermediate in the partly metastatic 168 FARN
cells and lowest in the highly metastatic 4T1 cells. This
could be explained, at least in part, by different expres-
sions of Brg-1 as well as different Brg-1 binding levels at
the SPARC promoter among the three cell lines.
Fenretinide has been shown to induce apoptosis lead-
ing to inhibition of mammary carcinogenesis [46,47]; it
has also been shown to reduce the occurrence of sec-
ondary breast cancer in women aged 40 years or
younger [45]. Our results demonstrated that fenretinide
has the ability to induce the expression of Brg-1, which
can explain one of the possible mechanisms responsible
for the chemopreventive potential of this drug. It has
been reported that a variety of human malignancies are
associated with mutations of Brg-1, thus suggesting that
Brg-1 may play an important role in tumor suppression
Figure 9 Fenretinide-induced transactivation and expression of
SPARC depend on Brg-1. 4T1, 168FARN or 67NR cells were
respectively transfected with siRNA control (-) or siRNA specific for
Brg-1 (+). 24 hrs after transfection, cells were transiently co-
transfected again with the luciferase reporter vector pREP4-SP-Luc
and pRL-CMV. 6 hrs after the second transfection, cells were
cultured for 24 hrs with or without fenretinide (5 μM). Total protein
extracts were prepared. (A) The luciferase activities were analyzed by
the dual-luciferase reporter assay system. (B) Expression of SPARC
and Brg-1 proteins were analyzed using Western blot analysis. b-
actin was analyzed as a control. (C) Cells were transfected with Brg-
1 siRNA or control siRNA for 24 hrs and then treated with
fenretinide for 24 hrs. Total RNA was extracted and expression of
SPARC mRNA levels was measured by real-time RT-qPCR.
Experiments were conducted in quadruplicate and normalized to
GAPDH mRNA level. The relative SPARC mRNA level in control
siRNA-treated cells is set as 100% (data shown are mean ± SEM,
n = 4, **P < 0.001)
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blastoma tumor suppressor gene product (pRB), and
induce cell cycle arrest through the repression of E2F
target genes such as cyclin E, cyclin A, and CDC2
[66-68]. In addition, Brg-1 is also required for p53-and
BRCA-1-mediated transcriptional activation [32], as well
as tumor suppressor prohibitin- and HIC1-mediated
transcriptional repression. Brg-1 heterozygous mice
display higher susceptibility to mammary tumors [69],
while complete loss of Brg-1 enhances lung cancer
development [70]. Furthermore, Brg-1 has been demon-
strated to be silenced or mutated in various human
tumor cell lines derived from breast, ovarian, lung, brain
and colon cancers [71], and the loss of Brg-1 expression
is associated with a poor prognosis in lung cancer
patients [72]. Another study showed that Brg-1
Figure 10 SPARC is a mediator for fenretinide inhibiting cell invasion but not cell motility. (A) Cell motility was analyzed by in vitro
wound assay. 4T1 cells were grown on 24-well culture plates overnight and were then left untreated or pretreated with 2.5 μM or 5.0 μM
fenretinide for 6 hrs. The confluent cell monolayers were gently scratched with a pipette tip to produce a wound. After wash, the cells were
cultured in medium containing different combinations of fenretinide with anti-SPARC antibodies. Quantitative analysis was performed 18 hrs
later, as described in the Materials and Methods section. Data shown are means ± SEM. *P < 0.01. (B) In vitro invasion assay was performed using
24-well trans-well units with polycarbonate filters (pore size 8 μm) coated on the upper side with ECMatrix™. Cells pretreated or untreated with
fenretinide for 6 hrs were collected, and 5 × 10
4 cells in 0.3 ml of serum-free medium with different combinations of fenretinide with anti-SPARC
antibodies were placed in the upper part of the trans-well unit and allowed to invade for 24 hrs. The lower chamber of the plate was filled with
medium containing 10% FBS. The relative invasion of cells cultured in medium without fenretinide and anti-SPARC antibodies was considered as
100%. Results from three independent experiments were expressed as mean ± SEM. *P < 0.01, compared with untreated cells. **P < 0.01,
compared with cells treated with fenretinide alone.
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docrine carcinomas of the cervix [73]. The findings that
Brg-1 is frequent lost in primary and metastatic melano-
mas and it interacts with the melanoma-associated
tumor suppressor p16
INK4a imply an important role for
Brg-1 in melanoma [74]. All these data suggest that Brg-
1 may function as a tumor suppressor. Therefore, the
anti-cancer effects of fenretinide might be partly due to
its ability to induce Brg-1 expression. The induction of
Brg-1 expression in response to fenretinide and its
enhancing effect on apoptosis and tumor suppression
are certainly worthy of more extensive studies.
Besides Brg-1, we also found that SPARC expression
and secretion as well as SPARC promoter-driven tran-
scriptional activity were induced by fenretinide in tumor
cells. Moreover, our results revealed that knockdown of
Brg-1 inhibited the fenretinide-induced SPARC expres-
sion and SPARC promoter-driven transcriptional activ-
ity. Together with these results, it is suggested that
fenretinide up-regulates the SPARC transcription via the
induction of Brg-1 expression. SPARC is an important
regulator of cell growth and malignancy with complex
biological effects that are cell- and tumor-type specific.
For example, in certain types of cancers, such as mela-
nomas and gliomas, SPARC is associated with a highly
aggressive tumor phenotype, while in others, mainly in
neuroblastomas, as well as in ovarian and colorectal
cancers, SPARC functions as a tumor suppressor [18].
The role of SPARC in the development and progression
of breast cancer is still not fully elucidated. Dhanesuan
et al. [9] revealed that SPARC can inhibit breast cancer
cell proliferation. A report using human MDA-MB231
breast cancer cells demonstrated that overexpression of
SPARC inhibited the metastatic capacity of these cells to
different organs, including lungs and bones [11]. Wong
and colleagues recently reported that 60% of patients
with low SPARC expression had metastases within 5
years of diagnosis, while only 33% of patients with high
SPARC-expression developed metastasis in the same
period [75]. Another recent study also revealed that
down-regulation of SPARC is correlated with poor prog-
nosis in breast cancer patients[76]. Therefore, these
results seem to support the anti-tumorigenic role of
SPARC. In this study, we detected the SPARC expres-
sion level and its secretion into milieu using three differ-
ent mammary carcinoma cell lines with different levels
of metastatic potential: highly metastatic 4T1, moder-
ately metastatic 168 FARN and non-metastatic 67NR
cell lines. The results showed that both SPARC gene
expression and secretion levels were negatively asso-
ciated with the metastatic capacity of tumor cells. We
also found that the invasion activity in 4T1 cells treated
with fenretinide was significantly decreased compared
with untreated cells. Cancer cells treated with a SPARC
antibody resulted in an abrogation of fenretinide-
induced decrease in cell invasion. These results suggest
t h a tf e n r e t i n i d ei sa b l et oi n d u c et h ee x p r e s s i o no f
SPARC gene, and as a consequence, to inhibit cancer
cell invasion.
Conclusions
In summary, we found that Sp1/Brg-1 complex is
involved in the constitutive expression of the SPARC
gene in mammary tumor cells. We also demonstrated
that fenretinide up-regulates SPARC transcription,
expression and secretion via the induction of Brg-1
expression and that SPARC plays an important role in
fenretinide-induced inhibition of cell invasion. Our find-
ings provide new insights for the understanding of the
anti-cancer effects of fenretinide on breast cancer.
Materials and methods
Cells and cell culture
Mammary tumor cell lines, 4T1, 168FARN and 67NR,
were generously provided by Dr. F. Miller (Barbara Ann
Karmanos Cancer Institute, MI, USA), and maintained
in DMEM supplemented with 7% fetal bovine serum
and 1% streptomycin-penicillin, and incubated in a
humidified atmosphere containing 5% CO2 at 37°C.
Plasmid constructs and reagents
pREP4-luc was constructed as described previously [77].
pREP-SP-luc was constructed by inserting the PCR-
amplified SPARC promoter (spanning nucleotides -201/
+19 of SPARC gene), using the forward primer (5′-
GAGCTAGCTGTCTGGGT AGCACACAGCCTAC-3′)
and reverse primer (5′-CAAAGCTTCTGAAGGGCTGC
AGGAATGTG-3′), into the NheI-HindIII sites of
pREP4-luc. Expression plasmid encoding human Brg-1
(pBJ5 BRG1) and the ATPase-defective variant of Brg-1
(pBJ5 BRG1 DN, K798R mutant) [78] were obtained
from AddGene (Cambridge, MA, USA), and human
Brg-1 was shown to be expressed correctly and work
properly in mouse cells and in frog oocytes [79,80].
Fenretinide (2,4,6,8-Nonatetraenamide, N-(4-hydroxy-
phenyl)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-
yl-(all-E); 374551) powder was generously provided by
Dr. R. Smith (NIH, Bethesda, Maryland, USA).
Western blot analysis
After appropriate treatments, cells were collected and
total cellular extracts or nuclear fractions were prepared.
Western blot analysis was then performed as described
previously [81]. A monoclonal antibody against b-actin
(Sigma, Saint Louis, MO, USA) was used at a 1:5,000
dilution. A monoclonal antibody against SPARC (R&D
systems, Minneapolis, MN, USA) was reconstituted at a
concentration of 500 μg/ml and used at a 1:2,500
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(sc10768×, Santa Cruz Biotechnology, Santa Cruz, CA,
U S A )o rS p 1( s c 1 4 0 2 7 × ,S a n t aC r u zB i o t e c h n o l o g y )w a s
used at a 1:4,000 dilution.
Immobilized-template assays
Immobilized-template assays were performed as
described previously [82]. Two hundred micrograms of
Dynabeads M280 streptavidin (Dynal) was prepared,
concentrated and resuspended in 20 μl of buffer T
(10 mM Tris [pH 7.5], 1 mM EDTA, 1 M NaCl) includ-
ing 10 pmol of biotinylated GGAGG-rich-containing
either probe a (spanning nucleotides -130/-56 of the
SPARC gene [gene bank accession #M20683]) or probe
b (spanning nucleotides -50/+19 of the SPARC gene).
The mixture was gently agitated for 1 hr at room tem-
perature (RT) and the beads were then washed 4 times
in buffer T to remove unbound probes. Bead-coupled
probes were equilibrated in buffer R (10 mM Tris [pH
7.5], 1 mM MgCl2, 0.1% NP-40, 1 mM EDTA, 10 mM
DTT, 5% glycerol, 60 mM KCl, 12 mM HEPES [pH
7.9], 0.03% BSA) for 30 min, centrifuged and resus-
pended in buffer R containing 200 μg of nuclear extract
and 40 ng/μl of poly (dG-dC) (120 μl final volume), and
agitated for 30 min at RT. After binding reaction, the
beads were washed three times using buffer R contain-
ing 10 ng/μl of poly (dG-dC). The bound proteins were
eluted by boiling them in SDS sample buffer, and the
presence of Brg-1, Sp1 and p38 were detected by Wes-
tern blot analysis.
Chromatin Immunoprecipitation (ChIP) assay, Re-ChIP and
ChIP-qPCR
The ChIP assay was performed using a chromatin
immunoprecipitation assay kit (Upstate, Lake Placid,
NY) according to the manufacturer’s instructions. Cells
were fixed with 1% formaldehyde for 10 min, washed
with ice-cold PBS containing protease inhibitors and
lysed with SDS lysis buffer. The lysate was sonicated to
yield DNA fragments between 300 and 1000 base pairs,
and centrifuged at 13,000 rpm for 10 min. The superna-
tant was diluted and pre-cleared with salmon sperm
DNA/protein A agarose. Immunoprecipitation was per-
formed overnight at 4°C using either non-specific IgG
or the antibodies against Brg-1 or Sp1. The immunopre-
cipitates were washed and eluted, and the cross-links
were reversed. The precipitated DNA fragments were
purified. The 5′-promoter region spanning nucleotide
positions -201 to -23 from the transcription start site of
the SPARC gene were amplified by PCR using 5′-
TGTCTGGGTAGCACACAGCCTAC-3′ and 5′-GCAG-
GAAGCCTCTT GGAGCTCT-3′ primers. Re-ChIP
assays utilized a similar protocol, except that the pri-
mary immunocomplex obtained with the Sp1 antibody
was eluted by 10 mM dithiothreitol with agitation at
37°C for 30 min. The eluate was diluted 50 times with
buffer (20 mM Tris-HCl, pH 8.1, 150 mM NaCl, 2 mM
EDTA, and 1% Triton X-100) and immunoprecipitated
using the second antibodies. For ChIP-qPCR assay, the
precipitated DNA fragments were purified and quanti-
fied with the Quant-iT™ dsDNA Assay Kit (Molecular
Probes, Eugene, Oregon) and were then amplified by
r e a l - t i m eq P C Ru s i n gt h es a m ep r i m e r sa sf o rr e g u l a r
PCR.
Quantitative real-time PCR
Total RNA was extracted from cells using TRIzol
Reagent (Invitrogen, Burlington, ON, Canada) according
to the manufacturer′s instructions. One μg of total RNA
was reverse-transcribed with the QuantiTect reverse
transcription kit (Qiagen, Mississauga, ON, Canada). An
equal amount of cDNA or purified DNA fragment from
ChIP was then amplified by real-time PCR using the
Stratagene Mx-4000 and Brilliant SYBR Green QPCR
Master Mix. Gene expression was normalized to a
house-keeping gene (GAPDH) and the relative expres-
sion values between the samples were calculated based
on the threshold cycle (CT) value using the 2
-ΔΔCT
method [83]. The following primers were used for
cDNA amplification: Brg-1, 5′-TCTGAGGTGGACGC
CCGACACATTA-3′ (forward) and 5′-TAAGGACCTGC
GTCAACTTGCAGTG-3′ (reverse); and SPARC,
5′-AGGTGTGTGAGCTGCACG AGA-3′ (forward) and
5′-GAAGTGGCAGGA AGAGTCGAA-3′(reverse).
Small RNA interference experiment
The transfection of siRNA into 4T1, 168FARN or 67NR
cells was performed in 6-well plates using the Lipofecta-
mine™ RNAiMAX (Invitrogen, Burlington, ON), accord-
ing to the manufacturer’s instructions. One day before
transfection, cells were seeded at an appropriate density
to give 40~50% confluence at the time of transfection.
The siRNAs against Brg-1, Sp1 and control siRNA were
purchased from Santa Cruz Biotechnology, Inc. (Santa
Cruz, CA). Cells were harvested for assays 48 hrs or
72 hrs after transfection with these siRNAs. To assess
luciferase activity, the cells were transfected 24 hrs after
siRNA transfection with 1.8 μg of the luciferase reporter
constructs and 100 ng of Renilla luciferase control vec-
tor (pRL-CMV). 24 hrs later, the cells were treated with
fenretinide for another 24 hrs and luciferase activity was
measured.
Immunoprecipitation assays
Cells were washed once with ice-cold PBS and lysed in
EBMK/0.1% NP-40 buffer (25 mM HEPES, pH 7.6,
5m MM g C l 2, 1.5 mM KCl, 75 mM NaCl, 175 mM
sucrose, 0.1% NP-40 and protease inhibitors) on ice for
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tion at 500 × g for 4 min. and washed three times with
EBMK buffer (no NP-40). The nuclei were then lysed in
1 ml of RIPA buffer containing protease inhibitors,
passed repeatedly through a 22-gauge needle and centri-
fuged at 10,000 × g for 30 min. The supernatants were
pre-cleared with protein A/G agarose for 30 min.
Immunoprecipitation was performed overnight at 4°C
using the antibody against Brg-1 or Sp1. To precipitate
the antigen-antibody complex, protein A/G agarose was
added and incubated for 1 hr at 4°C. After washing with
RIPA buffer, the precipitated proteins were eluted by
boiling in 2× SDS sample buffer and analyzed by immu-
noblotting using antibodies to Brg-1 or Sp1.
Luciferase activity
Transient transfections of 4T1, 168FARN or 67NR cells
were performed using the Lipofectamine™ 2000 and Plus
reagent (Invitrogen, Burlington, ON) according to man-
ufacturer’s instructions. Briefly, cells were seeded into
12-well plates one day before transfection at a density of
5×1 0
4 cells (4T1 or 168FARN) or 1 × 10
5 cells (67NR)
per well. Cells were transfected with 1.8 μgl u c i f e r a s e
reporter constructs and 100 ng of Renilla luciferase con-
trol vector (pRL-CMV). 24 hrs after transfection, cells
were treated with fenretinide or left untreated for 24 hrs
before harvest. Luciferase reporter assays were per-
formed using the Dual-Luciferase® Reporter Assay Sys-
tem (Promega, Madison, WI) and the luminescence
measurements were done with a Turner Designs model
TD-20/20 luminometer. Firefly luciferase activity was
normalized to Renilla luciferase activity. Each transfec-
tion was done in triplicate and repeated three times.
Measuring secreted SPARC
Following the treatment of cells with siRNA or fenreti-
nide, cell media were collected and centrifuged to
remove cell debris. Equal volumes (15 μl) of supernatant
were used for Western blot analysis. Densitometric
quantitation was performed, and to correct for any
potential discrepancy in cell number resulting from dif-
ferent experimental conditions, the densitometric results
were adjusted for total protein contents of cell lysates.
In vitro wound healing assay
Cells were seeded in 24-well culture plates at 1.5 × 10
5
cells/well. After 18 hrs, the cells were left untreated or
pretreated with 2.5 μMo r5 . 0μM fenretinide for 6 hrs
before wound formation. The in vitro ’scratch’ wounds
were created by scraping the confluent cell monolayer
with a 200 μl pipette tip and cultures were then washed
twice with PBS to remove floating cells. Cells were then
cultured in fresh medium or medium containing 2.5 μM
or 5.0 μM fenretinide alone or combined with 8 μg/ml
goat nonspecific IgG or SPARC antibody (R&D sys-
tems). The plates were photographed at 0 hr and 18 hrs
after treatment. The wound width was measured using
the program Image J http://rsbweb.nih.gov/ij/ between
two certain points on either side of the gap. For proper
statistical evaluation, at least three measurements at dif-
ferent points were performed at each image. The wound
width at the 18-hr time point was subtracted from that
at the 0-hr time point. The distance was normalized to
the wound width at 0 hr. The values were then
expressed as relative motility, setting the cell motility of
untreated cells as 100%. Three independent experiments
were done in triplicates.
Invasion assay
Cell invasion ability was assessed using a cell invasion
assay kit (Chemicon International, Temecula, CA, USA)
according to the manufacturer’s instructions. The assay
was performed in an invasion chamber, which consists of
a 24-well tissue culture plate containing 12 cell culture
inserts. The inserts contain an 8-μm pore size polycarbo-
nate membrane coated on the upper side with a thin
layer of ECMatrix™. Cells were pretreated with 2.5 μMo r
5.0 μM fenretinide or left untreated for 6 hrs and were
then collected and counted. 5 × 10
4 untreated cells were
resuspended in 0.3 ml of serum-free medium and pre-
treated cells were resuspended in 0.3 ml of serum-free
medium containing 2.5 μM or 5.0 μM fenretinide only or
combined with goat nonspecific IgG (5 μg/ml) or SPARC
antibody (5 μg/ml). The lower chamber of the plate was
filled with 0.5 ml medium containing 10% FBS with or
without fenretinide. The cell suspension was then placed
in the upper chamber and incubated at 37°C for 24 hrs.
The noninvasive cells on the upper side of the membrane
w e r er e m o v e d .T h ei n v a s i v ec e l l so nt h el o w e rs u r f a c eo f
the membrane were stained and then lysed. Absorbance
was measured with a microplate reader at 560 nm. Each
experiment was repeated three times, and the data repre-
sent the mean ± SEM of three determinations.
Statistical analysis
All data are presented as means ± SEM of three or four
experiments. Analysis was performed using unpaired
Student’s t test. P < 0.05 was considered significant.
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